Inclusion Criteria:  Men and women age of 18 years old and older. HCV chronic Infection, genotype 1 or 2 or 3 or 4 or 5 or 6 Naive Bi-therapy failure, Tri-therapy 1st generation Telaprévir and Boceprevir, Sofosbuvir - pegIFN - RBV failure Evaluation of fibrosis by non-invasive methods (Fibroscan, Fib 4, APRI) performed during the pre-inclusion period (of at least one month) or A Liver biopsy puncture of at least 24 months before the inclusion visit. Fibrosis according to Metavir score: F0, F1, F2, F3, F4. Compensated Cirrhosis Child-Pugh A or Decompensated Cirrhosis (This point is applicable for patients who have cirrhosis)  Exclusion Criteria:  Patient under amiodarone Hepatocellular carcinoma HCC Haemodialysis Creatinine Clearance < 30ml/min Breastfeeding Impossibility of using effective masculine or feminine contraception during the study and 6 months after treatment cessation. Medications triggering conduction disturbances with long QT, 30 days prior to inclusion QT prolongation > 450 ms Personal or familial history of torsade de pointes Allergies to nucleosi(ti)des analogues. Advanced cardiopulmonary pathology Malignant neoplasia The intake of anticonvulsants: Carbamazepine, eslicarbazepine, fosphenytoin, phenytoin, oxcarbazepine, pentobarbital, phenobarbital, primidone or the antimycobacterial agents: Rifabutin, rifampin